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Abstract
Background: IDH mutations have been demonstrated to confer prolonged survival in patients suffering from
gliomas, but the mechanisms underlying the improved prognosis are unclear. While some studies have attributed
these observations to an enhanced sensitivity to genotoxic therapies, others have postulated that IDH-mutated
gliomas exhibit less aggressive intrinsic biological behavior, including the propensity to invade distant sites.
Although most gliomas recur local to the site of initial presentation, some tumors demonstrate distant recurrence,
the vast majority of which involve the contralateral hemisphere. Trans-tentorial spread has been described once
before, in which a supratentorial glioblastoma was reported to recur infratentorially in the cerebellum.
Case presentation: We describe a patient who underwent surgical resection, followed by adjuvant radiation and
temozolomide of a World Health Organization (WHO) III anaplastic astrocytoma in the right temporal lobe,
exhibiting an IDH1 (R132H) mutation. Twenty-two months after surgery, he developed a second lesion, located in
the right cerebellum, suspicious for recurrent tumor versus radiation necrosis. A second surgery was performed, and
pathology demonstrated recurrent tumor, consistent with IDH1-mutated anaplastic astrocytoma.
Conclusions: This is the first example of trans-tentorial spread in an IDH-mutated glioma, suggesting that
despite improved survival, IDH mutations may not preclude gliomas from exhibiting the ability to invade
distant sites of the brain.
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Background
Gliomas are malignant tumors arising from astrocytes
within the brain and are classified into grades II to IV,
based on histopathological criteria set forth by the
World Health Organization (WHO). In recent years,
mutations in isocitrate dehydrogenase 1 (IDH1) and
IDH2 have been shown to characterize low-grade glioma
and secondary glioblastomas [1]. Moreover, IDH muta-
tions confer a significant survival benefit, compared to
their wild type counterparts, across all WHO grades [2].
As such, routine assessment of IDH mutation status is
becoming increasingly commonplace in the clinical
setting.
It is well known that gliomas frequently recur despite
optimal surgery and adjuvant radiation and chemother-
apy. Up to 90 % of all recurrences are found within 2–
3 cm from the area of initial presentation [3, 4], while
recurrence involving the contralateral hemisphere occurs
in up to 4 % of cases [5]. The role of IDH mutations in
the propensity for distant recurrence is unclear although
some evidence suggests that IDH wild-type gliomas may
have a stronger predilection for such behavior [5].
In this report, we describe a patient who underwent
surgical resection of a right temporal lobe WHO III
IDH1-mutated anaplastic astrocytoma, followed by adju-
vant radiation and temozolomide. Twenty-two months
after surgery, he developed a second lesion in the right
cerebellum, for which he underwent total resection.
Pathology again demonstrated an IDH-mutated anaplas-
tic astrocytoma, suggesting similar origin from the ori-
ginal tumor. Our patient is the first example of an IDH-
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mutated glioma exhibiting behavior of trans-tentorial re-
currence. As such, IDH mutations, despite association
with improved survival, may not preclude the ability of
gliomas to recur distantly from the initial site of
presentation.
Case presentation
A 34-year-old male was incidentally found to have bilat-
eral papilledema on a routine ophthalmological exam.
His past medical history was significant for two episodes
of generalized tonic-clonic seizures with negative work-
up on imaging, for which he was on anti-convulsant
medication. To further evaluate his papilledema, he was
sent to the emergency department of a nearby hospital
for further evaluation where a non-contrast CT showed
a 3.7-cm hypo-dense mass in the right temporal lobe as-
sociated with 6 mm of leftward midline shift. A brain
MRI re-demonstrated a non-enhancing lesion in the
right temporal lobe (Fig. 1a) with significant peri-
tumoral edema (Fig. 1b) that extended superiorly into
the right fronto-parietal lobes and across the corpus cal-
losum (Fig. 1c). There was no evidence of additional dis-
ease within the infra-tentorial compartment, including
the cerebellum (Fig. 1d). Subsequently, the patient
underwent subtotal resection of the temporal lesion with
final pathology demonstrating a WHO III anaplastic as-
trocytoma (Fig. 2a) with intact 1p/19q chromosomal
arms and positive for the IDH1 (R132H) mutation, based
on immunohistochemical staining (Fig. 2b). The tumor
exhibited a moderate mitotic index of 5 % (Fig. 2c).
After surgery, the patient was referred to the neuro-
oncology branch of our institution for further manage-
ment of his condition. Two months after the surgery,
the whole tumor bed was radiated over 30 fractions to a
total of 60 Gy but given the large volume of the radi-
ation field, concurrent temozolomide was deferred to re-
duce risk of radiation-induced necrosis. Over the next
year, he received 12 cycles of adjuvant temozolomide,
which he tolerated well. Serial MRIs demonstrated
attenuation of fluid-attenuated inversion recovery
(FLAIR) signal abnormality, and clinically, the patient
was doing very well and remained free of neurological
symptoms.
Over the next year and a half, routine surveillance im-
aging obtained at approximate 6-month intervals
showed local disease control and absence of distant re-
currence. However, on an MRI taken 22 months after
initial surgery, a new enhancing nodule was found in the
right cerebellum (Fig. 3a) with local edema (Fig. 3b). The
patient also co-incidentally described a 1-month history
of imbalance particularly upon changing positions from
sitting to standing. This lesion was felt to likely repre-
sent recurrent tumor although trans-tentorial spread
would have been uncommon. Delayed radiation necrosis
was also a possibility, given that upon review of radiation
records, the affected area in the cerebellum had received
54–57 Gy. To guide in treatment decision-making, a de-
finitive diagnosis was sought in the form of surgical re-
section of this lesion. Final pathological review of the
specimen demonstrated an IDH1 (R132H)-mutated
WHO III anaplastic astrocytoma (Fig. 4a, b). These find-
ings were consistent with those from the patient’s first
resection and were indicative of recurrent tumor. How-
ever, the mitotic index was markedly elevated at 40 %
(Fig. 4c) compared to 5 % from the first surgery. As
such, alternative chemotherapy was pursued, and the pa-
tient at the time of the reporting of this case was under
treatment with procarbazine and CCNU.
Discussion
Gliomas arising within the cerebellum are rare and re-
portedly make up 0.4–3.4 % of all gliomas, the majority
of which present as grade IV glioblastoma [6]. However,
cerebellar gliomas secondary to spread from a supraten-
torial tumor are exceedingly uncommon and, among
previous case reports, have been limited to a single study
by van Nifterik et al. [7]. The authors described a 31-
year-old male who initially underwent subtotal resection
Fig. 1 Imaging features of the initial tumor. a T1-weighted post-contrast and b T2-weighted MRI demonstrated a non-enhancing lesion in the
right temporal lobe. Edema extended superiorly on T2-weighted MRI (c) to involve the fronto-parietal lobes and corpus callosum. d T2-weighted
FLAIR MRI did not reveal any disease in the cerebellum
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of a left frontal glioblastoma multiforme (GBM),
followed by external-beam radiotherapy (42 Gy in 3-Gy
daily fractions) and single-fraction stereotactic boost
(15 Gy) to the residual mass. Twenty months after sur-
gery, he demonstrated tumor recurrence involving the
center of the cerebellum, which was diagnosed as recur-
rent GBM after surgical resection. Genetic analyses of
both tumors revealed identical loss of heterozygosity at
TP53 along with absence of PTEN loss and EGFR ampli-
fication. IDH mutation status was not performed in this
study given that the discovery of IDH mutations in glio-
magenesis was published 3 years after this report. As
such, our patient represents the second case of a supra-
tentorial glioma recurring trans-tentorially and involving
the cerebellum. Furthermore, unlike the report by van
Nifterik et al. [7], our patient’s tumor exhibited WHO III
grading, suggesting that trans-tentorial spread may not
be a characteristic limited to the biology of WHO IV gli-
omas, alone.
It is unclear whether the improved prognosis associ-
ated with IDH mutations is due to an enhanced sensitiv-
ity to chemo- and radiotherapies or to less aggressive
intrinsic biological behaviors. In support of the former
possibility, two large-scale studies demonstrated that
IDH mutations conferred higher response rates to temo-
zolomide and combination procarbazine, lomustine, and
vincristine therapy in low-grade gliomas and oligo-
dendrogliomas, respectively [8, 9]. However, other stud-
ies in similar patient cohorts have failed to reproduce
these findings [10, 11]. Likewise, in support of attenu-
ated biology, IDH-mutated tumors may be more amen-
able to surgical resection [12], potentially due to
favorable MRI characteristics, including reduced con-
trast enhancement, unilateral growth patterns, and
sharper tumor margins [13]. When analyzing patterns of
recurrence as a correlate of intrinsic biologic behavior, re-
cent evidence also suggests that IDH mutations may pre-
dict a more benign clinical course. Recently, Shibahara et
al. demonstrated that IDH wild-type WHO III anaplastic
astrocytomas had significantly higher rates of distant re-
currence along with increased expression of glioma stem
cell markers compared to their IDH-mutated histological
counterparts [14]. Out of 86 total patients, 15 exhibited
distant recurrence, among which only 3 were IDH-
Fig. 2 Histopathological features of the initial tumor. a A routine H&E stain demonstrated hypercellularity, nuclear atypia, and mitotic figures suggestive
of anaplastic astrocytoma. b Immunohistochemical staining showed positivity for the IDH1 (R132H) mutation. c MIB-1 immunohistochemical staining
showed a mitotic index of approximately 5 %
Fig. 3 Imaging features of the recurrent tumor. a T1-weighted post-contrast and b T2-weighted MRI demonstrated an enhancing lesion in the
right cerebellum with peri-lesional edema
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mutated, none of which involved trans-tentorial spread
like our patient. The authors concluded that IDH wild-
type WHO III gliomas may behave more aggressively,
more similarly to WHO IV glioblastomas. In regard to our
patient, despite first-line treatment with temozolomide
and radiation after initial tumor resection, our patient de-
veloped disease recurrence in a relatively short period of
time and had distant recurrence. As such, the fact that our
patient’s tumor was both treatment-refractory and be-
haved invasively suggests further factors contributed to its
unusual clinical course. As no standard of care currently
exists for initial treatment of WHO III astrocytic gliomas
[15], we must consider the possibility that temozolomide
treatment induced mutagenic changes, which led to
heightened tumor aggression. This is supported by find-
ings from Johnson et al., who demonstrated that treatment
of low-grade gliomas with temozolomide could promote a
hypermutated phenotype at recurrence and malignant
progression into WHO IV glioblastoma [16]. Further in-
vestigation of our patient’s tumor is warranted to identify
additional features that contributed to its unusual clinical
course.
Conclusions
Although debate continues over the underlying mechan-
ism of increased survival observed in IDH-mutated gli-
omas, our patient demonstrates that IDH-mutated
tumors are indeed capable of trans-tentorial spread and
may not require WHO IV histopathological characteris-
tics to manifest such invasive features. Regardless, the
surgical approach for such diffusely infiltrating gliomas
is challenging but continues to involve maximal surgical
resection of areas involving contrast enhancement and
FLAIR signal abnormalities [17]. For recurrent tumors,
repeat cytoreductive surgery may confer additional sur-
vival for patients [18]. In rare cases of distant tumor re-
currence, the role of surgery is less clear, but as our case
demonstrates, surgery can help differentiate between
tumor recurrence and radiation necrosis, which may
subsequently affect treatment decision-making. Add-
itional reports are needed to determine the optimal
management of these patients and also further
characterize patterns of distant recurrence in IDH-
mutated gliomas.
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Fig. 4 Histopathological features of the recurrent tumor. a A routine H&E stain showed histopathology similar to the initial tumor, including
hypercellularity and anaplasia. b Immunohistochemical staining was again positive for the IDH1 (R132H) mutation. c MIB-1 immunohistochemical
staining demonstrated a mitotic index of 40 %, which was significantly elevated in comparison to the initial lesion
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